Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Neoplasms 28Lung Neoplasms 24Neoplasm Metastasis 12Mesothelioma, Malignant 11Mesothelioma 10Colorectal Neoplasms 10Ovarian Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Melanoma 5Head and Neck Neoplasms 5Breast Neoplasms 5Adenocarcinoma of Lung 5Pancreatic Neoplasms 4Carcinoma 4Advanced Cancer 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Lymphoma 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Advanced Solid Tumors 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2

Interventions

Oxaliplatin 31Fluorouracil 31Leucovorin 29Irinotecan 23Cetuximab 20Bevacizumab 16Capecitabine 13Gemcitabine 11pembrolizumab 8Folfox protocol 7Cisplatin 7Carboplatin 7Paclitaxel 6Nivolumab 6Cyclophosphamide 6trifluridine tipiracil drug combination 5cediranib 5Erlotinib Hydrochloride 5adagrasib 4Ipilimumab 4IFL protocol 4Floxuridine 4Bortezomib 4veliparib 3trametinib 3sargramostim 3poly ICLC 3binimetinib 3Trifluridine 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Colonic Neoplasms × Pemetrexed × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Pfizer

Phase 1 Terminated
30 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06447662 2026-04-20

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Pfizer

Phase 1 Recruiting
330 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡